The General Meeting of Shareholders of bioMérieux, a world leader in the field of in vitro diagnostics, today approved the appointment of two new independent directors, Agnès Lemarchand and Philippe Gillet.
Amid the growing global threat from antibiotic resistant organisms, bioMérieux is leveraging its robust history of fighting infectious diseases to provide solutions and services that aid Antibiotic Stewardship Programs.
bioMérieux, a world leader in the field of in vitro diagnostics, today announced that BioFire, its new molecular biology affiliate, received U.S. Food and Drug Administration (FDA) 510(k) clearance for the FilmArray® Gastrointestinal (GI) Panel1.
Alexandre Mérieux will take on the role of Chief Executive Officer of bioMérieux and head its Management Committee. To step up the rollout of its strategic plan, a new organization is being deployed.
bioMérieux participated at the Triangle SciTech Expo by creating a fun and educational exhibit exposing youth to the microbiology field at the North Carolina Museum of Natural Sciences in Raleigh, NC.
The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met yesterday and approved the consolidated financial statements for the year ended December 31, 2013.
VIDAS® C. difficile GDH is the 100th assay for use on VIDAS® range VIDAS® C. difficile GDH is the only FDA-approved automated immunoassay parameter for GDH* detection * Glutamate dehydrogenase
BioFire Diagnostics, LLC today announced that it has submitted the FilmArray Gastrointestinal (GI) Panel to the U.S. Food and Drug Administration (FDA) for 510(k) clearance.
bioMérieux, Inc. and Clarient, a GE Healthcare Company today announced that bioMérieux‘s molecular diagnostic test THxID®-BRAF has been added to the service offerings provided by Clarient.
